Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.
Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.
复制标题
DOI:
10.1016/j.isci.2021.103602
复制
发表时间:
2022-01-21
期刊:
影响因子:
5.8
通讯作者:
Carnahan RH
中科院分区:
文献类型:
--
作者:
Gilchuk P;Thomsen I;Yoder S;Brady E;Chappell JD;Stevens LJ;Denison MR;Sutton RE;Chen RE;VanBlargan LA;Suryadevara N;Zost SJ;Schmitz J;Pulley JM;Diamond MS;Rhoads JP;Bernard GR;Self WH;Rice TW;Wheeler AP;Crowe JE Jr;Carnahan RH
The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food and Drug Administration-approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardized quantitative neutralization assays. We report a high-throughput two-step profiling approach for identifying neutralizing convalescent plasma. Screening and downselection for serum antibody binding to the receptor-binding domain are followed by quantitative neutralization testing using a chimeric vesicular stomatitis virus expressing spike protein of SARS-CoV-2 in a real-time cell analysis assay. This approach enables a predictive screening process for identifying plasma units that neutralize SARS-CoV-2. To calibrate antibody neutralizing activity in serum from convalescent plasma donors, we introduce a neutralizing antibody standard reagent composed of two human antibodies that neutralize SARS-CoV strains, including SARS-CoV-2 variants of concern. Our results provide a framework for establishing a standardized assessment of antibody-based interventions against COVID-19. A high-throughput approach enabling antibody activity testing in COVID-19 plasma SARS-CoV-2 IgG binding screen coupled with quantitative neutralization testing Neutralization testing is necessary for profiling COVID-19 convalescent plasma Two broad monoclonal antibodies identified as a neutralization testing standard Immunology; Virology
登录
查看更多内容
影响因子:
2.9
作者:
Gniadek TJ;Thiede JM;Matchett WE;Gress AR;Pape KA;Fiege JK;Jenkins MK;Menachery VD;Langlois RA;Bold TD
通讯作者:
Bold TD
影响因子:
9.4
作者:
Addetia A;Crawford KHD;Dingens A;Zhu H;Roychoudhury P;Huang ML;Jerome KR;Bloom JD;Greninger AL
通讯作者:
Greninger AL
影响因子:
30.3
作者:
Case, James Brett;Rothlauf, Paul W.;Whelan, Sean P. J.
通讯作者:
Whelan, Sean P. J.
影响因子:
17.1
作者:
Jones BE;Brown-Augsburger PL;Corbett KS;Westendorf K;Davies J;Cujec TP;Wiethoff CM;Blackbourne JL;Heinz BA;Foster D;Higgs RE;Balasubramaniam D;Wang L;Zhang Y;Yang ES;Bidshahri R;Kraft L;Hwang Y;Žentelis S;Jepson KR;Goya R;Smith MA;Collins DW;Hinshaw SJ;Tycho SA;Pellacani D;Xiang P;Muthuraman K;Sobhanifar S;Piper MH;Triana FJ;Hendle J;Pustilnik A;Adams AC;Berens SJ;Baric RS;Martinez DR;Cross RW;Geisbert TW;Borisevich V;Abiona O;Belli HM;de Vries M;Mohamed A;Dittmann M;Samanovic MI;Mulligan MJ;Goldsmith JA;Hsieh CL;Johnson NV;Wrapp D;McLellan JS;Barnhart BC;Graham BS;Mascola JR;Hansen CL;Falconer E
通讯作者:
Falconer E
DOI:
10.1056/nejmoa2035389
发表时间:
2021-02-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者:
COVE Study Group